The stock of Dynavax Technologies Corporation (NASDAQ:DVAX) is a huge mover today! About 763,305 shares traded hands. Dynavax Technologies Corporation (NASDAQ:DVAX) has declined 57.05% since April 4, 2016 and is downtrending. It has underperformed by 58.14% the S&P500.
The move comes after 9 months positive chart setup for the $393.54 million company. It was reported on Nov, 4 by Barchart.com. We have $21.37 PT which if reached, will make NASDAQ:DVAX worth $460.44M more.
Dynavax Technologies Corporation (NASDAQ:DVAX) Ratings Coverage
Out of 2 analysts covering Dynavax Technologies (NASDAQ:DVAX), 0 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 0 are positive. Dynavax Technologies has been the topic of 4 analyst reports since August 12, 2015 according to StockzIntelligence Inc. The firm has “Outperform” rating by RBC Capital Markets given on Monday, November 30. On Wednesday, April 27 the stock rating was downgraded by JP Morgan to “Neutral”. RBC Capital Markets downgraded the stock to “Sector Perform” rating in Thursday, April 28 report. Zacks upgraded it to “Hold” rating and $33 target price in Wednesday, August 12 report.
According to Zacks Investment Research, “Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax’s clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.”
Insitutional Activity: The institutional sentiment decreased to 1.02 in Q2 2016. Its down 0.04, from 1.06 in 2016Q1. The ratio worsened, as 18 funds sold all Dynavax Technologies Corporation shares owned while 34 reduced positions. 10 funds bought stakes while 43 increased positions. They now own 31.67 million shares or 4.27% less from 33.08 million shares in 2016Q1.
Voya Invest Mngmt Ltd Liability Co has invested 0% of its portfolio in Dynavax Technologies Corporation (NASDAQ:DVAX). Moreover, Royal Comml Bank Of Canada has 0% invested in Dynavax Technologies Corporation (NASDAQ:DVAX) for 19,471 shares. Morgan Stanley has 290,285 shares for 0% of their US portfolio. Nelson Van Denburg And Campbell Wealth Grp Ltd Liability Company holds 0% or 100 shares in its portfolio. Mutual Of America Cap Llc has 0.01% invested in the company for 21,900 shares. Blackrock Institutional Tru Na reported 942,830 shares or 0% of all its holdings. Price T Rowe Associates Inc Md accumulated 25,780 shares or 0% of the stock. Teachers Advsr accumulated 0% or 62,022 shares. Blackrock holds 0% or 3,490 shares in its portfolio. Vanguard Gru has 1.52 million shares for 0% of their US portfolio. State Street Corporation, a Massachusetts-based fund reported 1.57 million shares. Cubist Systematic Strategies Limited Com has 0% invested in the company for 252 shares. The Maryland-based Howard Hughes Medical Institute has invested 0.1% in Dynavax Technologies Corporation (NASDAQ:DVAX). Legal General Public Ltd Liability Company has invested 0% of its portfolio in Dynavax Technologies Corporation (NASDAQ:DVAX). Schwab Charles Inv Mgmt, a California-based fund reported 131,952 shares.
Insider Transactions: Since May 12, 2016, the stock had 2 buys, and 0 selling transactions for $57,940 net activity. The insider Gray Eddie bought $42,820. Another trade for 1,000 shares valued at $15,120 was bought by Janssen Robert.
More news for Dynavax Technologies Corporation (NASDAQ:DVAX) were recently published by: Investorplace.com, which released: “Dynavax Technologies Corporation (DVAX) Injected With 20%-Plus Gains” on September 06, 2016. Fool.com‘s article titled: “Here’s Why Dynavax Technologies Corporation’s Stock Gained 14.5% In March” and published on April 09, 2016 is yet another important article.
DVAX Company Profile
Dynavax Technologies Corporation (Dynavax), incorporated on November 6, 2000, is a clinical-stage biopharmaceutical company. The Firm uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. The Company’s development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg). The Company’s lead cancer immunotherapy candidate is SD-101, a C Class CpG TLR9 agonist is selected for characteristics optimal for treatment of cancer, including high interferon induction. The Company’s SD-101 clinical program is intended to assess the preliminary efficacy of SD-101 in a range of tumors and in combination with a range of treatments. The Company’s advanced inflammatory disease candidate is AZD1419. The Company’s pipeline of product candidates for cancer immunotherapy includes DV281 and CpG-Nanoparticles, which are in the preclinical stage.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.